BR112012032055B8 - cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal - Google Patents

cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal Download PDF

Info

Publication number
BR112012032055B8
BR112012032055B8 BR112012032055A BR112012032055A BR112012032055B8 BR 112012032055 B8 BR112012032055 B8 BR 112012032055B8 BR 112012032055 A BR112012032055 A BR 112012032055A BR 112012032055 A BR112012032055 A BR 112012032055A BR 112012032055 B8 BR112012032055 B8 BR 112012032055B8
Authority
BR
Brazil
Prior art keywords
crystal
ylcarbonyl
methoxybutyl
morpholin
methylpropyl
Prior art date
Application number
BR112012032055A
Other languages
English (en)
Other versions
BR112012032055B1 (pt
BR112012032055A2 (pt
Inventor
Kitayama Masato
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112012032055A2 publication Critical patent/BR112012032055A2/pt
Publication of BR112012032055B1 publication Critical patent/BR112012032055B1/pt
Publication of BR112012032055B8 publication Critical patent/BR112012032055B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

cristal de cloridrato, medicamento, métodos para a profilaxia ou tratamento de uma doença e da hipertensão e/ou vários distúrbios de órgão, e, uso do cristal. é descrito um cristal de cloridrato de 1-(4- metoxibutil)-n- (2- metilpropil)-n- [(3s,5r)-5-(morfolin-4- ilcarbonil) piperidin-3-il ]-1h- benzimidazol-2- carboxamida que tem excelente atividade inibidora de renina e que é útil como um agente preventivo ou terapêutico para tipos de disfunção de órgão e os similares proveniente pressão sanguínea alta e hipertensão. o cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil) piperidin-3-il]-1h-benzimidazol-2-carboxamida tem um padrão de difração de raio x em pó em que o espaçamento do retículo cristalino do (d) da difração de raio x em pó tem picos característicos que aparecem na vicinidade de 26,43<sym> 0,2, 7,62<sym> 0,2 e 4,32<sym> 0,2 angstroms.
BR112012032055A 2010-06-16 2011-06-15 cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal BR112012032055B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010137194 2010-06-16
PCT/JP2011/063735 WO2011158880A1 (ja) 2010-06-16 2011-06-15 アミド化合物の結晶

Publications (3)

Publication Number Publication Date
BR112012032055A2 BR112012032055A2 (pt) 2016-11-08
BR112012032055B1 BR112012032055B1 (pt) 2019-10-22
BR112012032055B8 true BR112012032055B8 (pt) 2019-11-12

Family

ID=45348277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032055A BR112012032055B8 (pt) 2010-06-16 2011-06-15 cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal

Country Status (27)

Country Link
US (1) US9018374B2 (pt)
EP (1) EP2583967B1 (pt)
JP (1) JP5782438B2 (pt)
KR (1) KR20130119903A (pt)
CN (1) CN103068816B (pt)
AU (1) AU2011266099B2 (pt)
BR (1) BR112012032055B8 (pt)
CA (1) CA2802483C (pt)
CL (1) CL2012003526A1 (pt)
CO (1) CO6670573A2 (pt)
DO (1) DOP2012000313A (pt)
EA (1) EA022094B1 (pt)
EC (1) ECSP13012392A (pt)
ES (1) ES2524896T3 (pt)
GE (1) GEP20146195B (pt)
HK (1) HK1179605A1 (pt)
IL (1) IL223562A (pt)
MA (1) MA34378B1 (pt)
MX (1) MX2012014828A (pt)
MY (1) MY163927A (pt)
PE (1) PE20130283A1 (pt)
SG (1) SG186223A1 (pt)
TN (1) TN2012000589A1 (pt)
TW (1) TWI511967B (pt)
UA (1) UA108888C2 (pt)
WO (1) WO2011158880A1 (pt)
ZA (1) ZA201300065B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9382192B2 (en) * 2012-02-14 2016-07-05 Dow Global Technologies Llc Nonionic surfactant compositions
WO2013122260A1 (en) * 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
CN103831159B (zh) * 2014-01-20 2016-04-13 华润赛科药业有限责任公司 一种阿齐沙坦微粉化方法
EP3130581A4 (en) * 2014-04-10 2017-11-22 Takeda Pharmaceutical Company Limited Method for producing heterocyclic compound
GB2542876B (en) * 2015-04-20 2019-10-23 Johnson Matthey Plc Structure Directing Agent
CN107595853A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种用于治疗高血压合并冠心病的药物组合物及其用途
CN107595842A (zh) * 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种药物复方制剂及在制备治疗高血压合并冠心病的药物中的用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
AR041867A1 (es) 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2004092160A1 (ja) 2003-04-15 2004-10-28 Astellas Pharma Inc. 臭化物及びその結晶
JP3618341B2 (ja) * 2003-04-15 2005-02-09 山之内製薬株式会社 臭化物及びその結晶
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
US20060135523A1 (en) 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
EP1698624B1 (en) 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1897558B1 (en) 2005-06-09 2013-09-04 Norgine BV Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
RU2008108984A (ru) 2005-08-10 2009-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Терапевтический агент от диабета
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN102731451B (zh) 2006-06-27 2015-07-29 武田药品工业株式会社 稠环化合物
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
MX2009008103A (es) 2007-02-09 2009-08-18 Takeda Pharmaceutical Compuestos anulares fusionados como agonistas parciales de prar-gamma.
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
JP2010229034A (ja) 2007-07-26 2010-10-14 Dainippon Sumitomo Pharma Co Ltd 二環性ピロール誘導体
CN102123990B (zh) 2008-06-19 2014-07-09 武田药品工业株式会社 杂环化合物及其用途
JP4901849B2 (ja) 2008-12-15 2012-03-21 バブコック日立株式会社 空気清浄機、及び分析室、並びに空気の浄化方法
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity

Also Published As

Publication number Publication date
CN103068816A (zh) 2013-04-24
BR112012032055B1 (pt) 2019-10-22
DOP2012000313A (es) 2013-02-15
EP2583967B1 (en) 2014-10-01
ECSP13012392A (es) 2013-03-28
TN2012000589A1 (en) 2014-04-01
CA2802483C (en) 2017-10-24
EP2583967A1 (en) 2013-04-24
MY163927A (en) 2017-11-15
JPWO2011158880A1 (ja) 2013-08-19
ZA201300065B (en) 2014-03-26
ES2524896T3 (es) 2014-12-15
CO6670573A2 (es) 2013-05-15
AU2011266099B2 (en) 2014-09-11
GEP20146195B (en) 2014-11-10
MA34378B1 (fr) 2013-07-03
EP2583967A4 (en) 2013-09-04
US20130090337A1 (en) 2013-04-11
BR112012032055A2 (pt) 2016-11-08
PE20130283A1 (es) 2013-03-25
WO2011158880A1 (ja) 2011-12-22
UA108888C2 (xx) 2015-06-25
KR20130119903A (ko) 2013-11-01
US9018374B2 (en) 2015-04-28
SG186223A1 (en) 2013-01-30
TW201206914A (en) 2012-02-16
US20130252954A2 (en) 2013-09-26
CN103068816B (zh) 2015-01-07
EA201291453A1 (ru) 2013-05-30
CA2802483A1 (en) 2011-12-22
EA022094B1 (ru) 2015-10-30
JP5782438B2 (ja) 2015-09-24
TWI511967B (zh) 2015-12-11
HK1179605A1 (en) 2013-10-04
IL223562A (en) 2015-03-31
MX2012014828A (es) 2013-02-27
AU2011266099A1 (en) 2013-01-24
CL2012003526A1 (es) 2013-05-31

Similar Documents

Publication Publication Date Title
BR112012032055B8 (pt) cristal de cloridrato de 1-(4-metoxibutil)-n-(2-metilpropil)-n-[(3s,5r)-5-(morfolin-4-ilcarbonil)piperidin-3-il]-1h-benzimidazol-2-carboxamida, medicamento, e, uso do cristal
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
PH12013501790B1 (en) Use of dpp iv inhibitors
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
NZ600648A (en) Novel substituted triazole derivatives as gamma secretase modulators
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
BRPI0917315B8 (pt) anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
GT200800256A (es) Derivados de pirazolo [3,4-d]-pirimidina útiles para tratar trastornos respiratorios
PE20070333A1 (es) Composicion farmaceutica que comprende agomelatina para el tratamiento de transtornos del sueno en pacientes deprimidos
CL2008000127A1 (es) Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
AR056527A1 (es) Composicion farmaceutica para mejorar la funcion cognitiva
JP2015532296A5 (pt)
BR112012006010A2 (pt) composto de glicina
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
MA46268B1 (fr) Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu&#39;inhibiteurs doubles de phosphatidylinositol 3-kinase delta &amp; gamma
JP2008513426A5 (pt)
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
JP2010001264A5 (pt)
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
JP2011519873A5 (pt)
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
MA38697A1 (fr) 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2011, OBSERVADAS AS CONDICOES LEGAIS. (CO) REF. RPI 2546 DE 22/10/2019 QUANTO AO TITULO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2624 DE 20-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.